News
Quintiles and London Genetics Alliance T0 Enchance Drug Discovery and Development
Quintiles, the world’s leading bio pharmaceutical services company, and London Genetics, an expert in the use of pharmacogenetics in drug discovery and development, today announced a strategic alliance to offer the bio pharmaceutical industry innovative pharmacogenetics solutions to advance...
News
Vertex Completes New Drug Application for Telaprevir for Hepatitis C
Vertex Pharmaceuticals Incorporated announced that it has completed the submission of a New Drug Application (NDA) to the FDA seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C. The NDA submission is supported by results from...
News
Sun Pharma announces FDA tentative approval for generic Cymbalta
Sun Pharmaceutical Industries Ltd. announced US FDA has granted its subsidiary a tentative approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Cymbalta®, duloxetine hydrochloride delayed-release capsules. These generic duloxetine hydrochloride...
News
Lilly and Acrux Receive FDA Approval for Axiron Topical Solution CIII
Eli Lilly and Company and Acrux announced that the U.S. FDA has approved Axiron topical solution CIII for replacement therapy in men for certain conditions associated with a deficiency or absence of testosterone. Safety and efficacy of Axiron in...
News
VYTORIN the cholesterol-lowering medicine from Merck
In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck (known as MSD outside the US and Canada), VYTORIN 10/20 mg reduced the incidence of first major vascular events -- defined as non-fatal heart attacks or cardiac...
News
Antares Pharma Announces Next Generation of Auto-Injector Design
Antares Pharma, Inc., a leader in self-injection drug delivery technology, announced the latest advancement in its proprietary line of VIBEX(TM) auto-injectors. Antares' new VIBEX QS auto-injector platform offers a dose capacity of 1 mL and greater...
News
Pfizer Announces Positive Phase 3 Trial Results for Axitinib
Pfizer Inc.announced that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read